Cargando…

Drug Resistance Conferring Mutation and Genetic Diversity of Mycobacterium tuberculosis Isolates in Tuberculosis Lymphadenitis Patients; Ethiopia

BACKGROUND: Tuberculosis lymphadenitis (TBLN) is a growing public health concern in Ethiopia. However, there is limited information available on gene mutations conferring drug resistance and genetic diversity of M. tuberculosis isolates from TBLN patients. METHODS: Drug resistance and genetic divers...

Descripción completa

Detalles Bibliográficos
Autores principales: Ayalew, Sosina, Wegayehu, Teklu, Taye, Hawult, Wassie, Liya, Girma, Selfu, Berg, Stefan, Mihret, Adane
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7894881/
https://www.ncbi.nlm.nih.gov/pubmed/33623398
http://dx.doi.org/10.2147/IDR.S298683
_version_ 1783653318570016768
author Ayalew, Sosina
Wegayehu, Teklu
Taye, Hawult
Wassie, Liya
Girma, Selfu
Berg, Stefan
Mihret, Adane
author_facet Ayalew, Sosina
Wegayehu, Teklu
Taye, Hawult
Wassie, Liya
Girma, Selfu
Berg, Stefan
Mihret, Adane
author_sort Ayalew, Sosina
collection PubMed
description BACKGROUND: Tuberculosis lymphadenitis (TBLN) is a growing public health concern in Ethiopia. However, there is limited information available on gene mutations conferring drug resistance and genetic diversity of M. tuberculosis isolates from TBLN patients. METHODS: Drug resistance and genetic diversity analysis were done on 91 M. tuberculosis isolates from culture positive TBLN patients collected between 2016 and 2017. Detection of mutations conferring resistance was carried out using GenoType MTBDRplus VER 2.0. Thereafter, isolates were typed using spoligotyping. RESULTS: Out of the 91 strains, mutations conferring resistance to rifampicin (RIF) and isoniazid (INH) were observed in two (2.2%) and six (6.6%) isolates, respectively. The two RIF resistant isolates displayed a mutation at codon 531 in the rpoB gene with amino acid change of S531L. Among the six INH resistant strains, four isolates had shown mutation at the KatG gene at codon 315 with amino acid change of S315T, one isolate had a mutation at the inhA gene at codon 15 with amino acid change of C15T and one isolate had a mutation at the inhA gene with unknown amino acid change. All drug resistant isolates were from treatment naive TBLN patients. The dominantly identified Spoligo International Types (SITs) were SIT25, SIT149, and SIT53, respectively; these accounted for 43% of the total number of strains. The isolates were grouped into four main lineages; Lineage 1 (2, 2.2%), Lineage 3 (38, 41.7%), Lineage 4 (49, 53.8%) and Lineage 7 (2, 2.2%). Four out of six (66.7%) isolates with drug resistance conferring mutations belonged to clustered strains (strains with shared SIT). CONCLUSION: The detection of drug resistant conferring mutation in treatment naïve TBLN patients together with detection of drug resistant isolates among clustered strains might suggest resistant strains' transmission in the community. This needs to be carefully considered to prevent the spread of drug resistant clones in the country.
format Online
Article
Text
id pubmed-7894881
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-78948812021-02-22 Drug Resistance Conferring Mutation and Genetic Diversity of Mycobacterium tuberculosis Isolates in Tuberculosis Lymphadenitis Patients; Ethiopia Ayalew, Sosina Wegayehu, Teklu Taye, Hawult Wassie, Liya Girma, Selfu Berg, Stefan Mihret, Adane Infect Drug Resist Original Research BACKGROUND: Tuberculosis lymphadenitis (TBLN) is a growing public health concern in Ethiopia. However, there is limited information available on gene mutations conferring drug resistance and genetic diversity of M. tuberculosis isolates from TBLN patients. METHODS: Drug resistance and genetic diversity analysis were done on 91 M. tuberculosis isolates from culture positive TBLN patients collected between 2016 and 2017. Detection of mutations conferring resistance was carried out using GenoType MTBDRplus VER 2.0. Thereafter, isolates were typed using spoligotyping. RESULTS: Out of the 91 strains, mutations conferring resistance to rifampicin (RIF) and isoniazid (INH) were observed in two (2.2%) and six (6.6%) isolates, respectively. The two RIF resistant isolates displayed a mutation at codon 531 in the rpoB gene with amino acid change of S531L. Among the six INH resistant strains, four isolates had shown mutation at the KatG gene at codon 315 with amino acid change of S315T, one isolate had a mutation at the inhA gene at codon 15 with amino acid change of C15T and one isolate had a mutation at the inhA gene with unknown amino acid change. All drug resistant isolates were from treatment naive TBLN patients. The dominantly identified Spoligo International Types (SITs) were SIT25, SIT149, and SIT53, respectively; these accounted for 43% of the total number of strains. The isolates were grouped into four main lineages; Lineage 1 (2, 2.2%), Lineage 3 (38, 41.7%), Lineage 4 (49, 53.8%) and Lineage 7 (2, 2.2%). Four out of six (66.7%) isolates with drug resistance conferring mutations belonged to clustered strains (strains with shared SIT). CONCLUSION: The detection of drug resistant conferring mutation in treatment naïve TBLN patients together with detection of drug resistant isolates among clustered strains might suggest resistant strains' transmission in the community. This needs to be carefully considered to prevent the spread of drug resistant clones in the country. Dove 2021-02-15 /pmc/articles/PMC7894881/ /pubmed/33623398 http://dx.doi.org/10.2147/IDR.S298683 Text en © 2021 Ayalew et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Ayalew, Sosina
Wegayehu, Teklu
Taye, Hawult
Wassie, Liya
Girma, Selfu
Berg, Stefan
Mihret, Adane
Drug Resistance Conferring Mutation and Genetic Diversity of Mycobacterium tuberculosis Isolates in Tuberculosis Lymphadenitis Patients; Ethiopia
title Drug Resistance Conferring Mutation and Genetic Diversity of Mycobacterium tuberculosis Isolates in Tuberculosis Lymphadenitis Patients; Ethiopia
title_full Drug Resistance Conferring Mutation and Genetic Diversity of Mycobacterium tuberculosis Isolates in Tuberculosis Lymphadenitis Patients; Ethiopia
title_fullStr Drug Resistance Conferring Mutation and Genetic Diversity of Mycobacterium tuberculosis Isolates in Tuberculosis Lymphadenitis Patients; Ethiopia
title_full_unstemmed Drug Resistance Conferring Mutation and Genetic Diversity of Mycobacterium tuberculosis Isolates in Tuberculosis Lymphadenitis Patients; Ethiopia
title_short Drug Resistance Conferring Mutation and Genetic Diversity of Mycobacterium tuberculosis Isolates in Tuberculosis Lymphadenitis Patients; Ethiopia
title_sort drug resistance conferring mutation and genetic diversity of mycobacterium tuberculosis isolates in tuberculosis lymphadenitis patients; ethiopia
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7894881/
https://www.ncbi.nlm.nih.gov/pubmed/33623398
http://dx.doi.org/10.2147/IDR.S298683
work_keys_str_mv AT ayalewsosina drugresistanceconferringmutationandgeneticdiversityofmycobacteriumtuberculosisisolatesintuberculosislymphadenitispatientsethiopia
AT wegayehuteklu drugresistanceconferringmutationandgeneticdiversityofmycobacteriumtuberculosisisolatesintuberculosislymphadenitispatientsethiopia
AT tayehawult drugresistanceconferringmutationandgeneticdiversityofmycobacteriumtuberculosisisolatesintuberculosislymphadenitispatientsethiopia
AT wassieliya drugresistanceconferringmutationandgeneticdiversityofmycobacteriumtuberculosisisolatesintuberculosislymphadenitispatientsethiopia
AT girmaselfu drugresistanceconferringmutationandgeneticdiversityofmycobacteriumtuberculosisisolatesintuberculosislymphadenitispatientsethiopia
AT bergstefan drugresistanceconferringmutationandgeneticdiversityofmycobacteriumtuberculosisisolatesintuberculosislymphadenitispatientsethiopia
AT mihretadane drugresistanceconferringmutationandgeneticdiversityofmycobacteriumtuberculosisisolatesintuberculosislymphadenitispatientsethiopia